Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Tatsunori Miyata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4749-4741; OpenAlex author ID A5089439603. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
78
Papers, trials and grants by year

2018: 3 papers · 2019: 1 paper · 2020: 3 papers · 2021: 5 papers · 2022: none · 2023: 2 papers · 2024: none · 2025: none · 2026: 6 papers

Papers 20

  1. Preoperative Total Iron-Binding Capacity Is a Potential Surrogate Marker of Long-Term Outcomes After Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.1002/ags3.70297↗
  2. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  3. Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-18806-4↗
  4. ASO Author Reflections: Beware the Collaterals: Vein Formation Signals Higher Surgical Risk in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18960-9↗
  5. ASO Visual Abstract: Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-19046-2↗
  6. Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.18442↗
  7. Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis… Co-author DOI 10.1038/s41416-022-02106-9↗
  8. Statins exert anti-growth effects by suppressing YAP/TAZ expressions via JNK signal activation and eliminate the immune suppression by downregulating PD-L1 exp… Co-author PMID 37293171↗
  9. Recent advances in precision medicine for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12436↗
  10. Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.09.007↗
  11. Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Institution Study. Co-author DOI 10.1245/s10434-020-09022-3↗
  12. High ARHGEF2 (GEF-H1) Expression is Associated with Poor Prognosis Via Cell Cycle Regulation in Patients with Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09383-9↗
  13. Proteomic Analysis of Malignant Ascites From Patients With Pancreatic Ductal Adenocarcinoma. First author DOI 10.21873/anticanres.15071↗
  14. Postoperative nonalcoholic fatty liver disease is correlated with malnutrition leading to an unpreferable clinical course for pancreatic cancer patients underg… Co-author DOI 10.1007/s00595-019-01866-x↗
  15. ASO Author Reflections: Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single Institutio… Co-author DOI 10.1245/s10434-020-09039-8↗
  16. Efficacy of Staging Laparoscopy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14037↗
  17. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Co-author DOI 10.1111/cas.13874↗
  18. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2017.08.016↗
  19. Multiple Primary Cancers in Patients with Pancreatic Cancer. Co-author DOI 10.1177/000313481808401205↗
  20. Cystic gastric metastasis from pancreatic cancer. Co-author DOI 10.1186/s40792-018-0443-2↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromitsu Hayashi · 11 shared papers, 2020–2026 · strength 1.79
  2. Masaaki Iwatsuki · 5 shared papers, 2026 · strength 1.35
  3. Yuki Kitano · 9 shared papers, 2018–2026 · strength 1.14
  4. Hirohisa Okabe · 8 shared papers, 2018–2026 · strength 1.11
  5. Takanobu Yamao · 8 shared papers, 2018–2026 · strength 1.09
  6. Atsushi Oba · 4 shared papers, 2026 · strength 0.97
  7. Katsunori Imai · 9 shared papers, 2018–2023 · strength 0.92
  8. Yoshihiro Ono · 3 shared papers, 2026 · strength 0.78
  9. Yosuke Inoue · 3 shared papers, 2026 · strength 0.73
  10. Shigeki Nakagawa · 7 shared papers, 2018–2023 · strength 0.72
  11. Hideo Baba · 5 shared papers, 2019–2023 · strength 0.61
  12. Kota Arima · 7 shared papers, 2018–2021 · strength 0.57
  13. Akira Chikamoto · 6 shared papers, 2018–2021 · strength 0.49
  14. Takashi Sasaki · 2 shared papers, 2026 · strength 0.48
  15. Aya Maekawa · 2 shared papers, 2026 · strength 0.48
  16. Masato Ozaka · 2 shared papers, 2026 · strength 0.48
  17. Tomotaka Kato · 2 shared papers, 2026 · strength 0.48
  18. Naoki Sasahira · 2 shared papers, 2026 · strength 0.48
  19. Norio Uemura · 3 shared papers, 2021–2023 · strength 0.45
  20. Kazuki Matsumura · 3 shared papers, 2021–2023 · strength 0.44
  21. Masayo Tsukamoto · 5 shared papers, 2018–2021 · strength 0.42
  22. Naoki Umezaki · 5 shared papers, 2018–2021 · strength 0.42
  23. Yosuke Nakao · 4 shared papers, 2020–2021 · strength 0.41
  24. Rumi Itoyama · 4 shared papers, 2020–2021 · strength 0.41
  25. Takatsugu Ishimoto · 4 shared papers, 2018–2021 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.